entinostat has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entinostat treatment was able to reduce the CD44(high)/CD24(low) cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4." | 1.42 | Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. ( Kazi, A; Sabnis, G; Schech, A; Shah, P; Yu, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, XC | 1 |
| Tu, FH | 1 |
| Wei, LY | 1 |
| Wang, BZ | 1 |
| Yuan, H | 1 |
| Yuan, JM | 1 |
| Rao, Y | 1 |
| Huang, SL | 1 |
| Li, QJ | 1 |
| Ou, TM | 1 |
| Wang, HG | 1 |
| Tan, JH | 1 |
| Chen, SB | 1 |
| Huang, ZS | 1 |
| Hicks, KC | 1 |
| Knudson, KM | 1 |
| Lee, KL | 1 |
| Hamilton, DH | 1 |
| Hodge, JW | 1 |
| Figg, WD | 1 |
| Ordentlich, P | 1 |
| Jones, FR | 1 |
| Rabizadeh, S | 1 |
| Soon-Shiong, P | 1 |
| Schlom, J | 1 |
| Gameiro, SR | 1 |
| Merino, VF | 1 |
| Cho, S | 1 |
| Nguyen, N | 1 |
| Sadik, H | 1 |
| Narayan, A | 1 |
| Talbot, C | 1 |
| Cope, L | 1 |
| Zhou, XC | 1 |
| Zhang, Z | 1 |
| Győrffy, B | 1 |
| Sukumar, S | 1 |
| Maiti, A | 1 |
| Qi, Q | 1 |
| Peng, X | 1 |
| Yan, L | 1 |
| Takabe, K | 1 |
| Hait, NC | 1 |
| Schech, A | 1 |
| Kazi, A | 1 |
| Yu, S | 1 |
| Shah, P | 1 |
| Sabnis, G | 1 |
5 other studies available for entinostat and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Histone Deacetylase Inh | 2022 |
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Topics: Animals; Apoptosis; Benzamides; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Proliferation; Col | 2020 |
Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Breast; Cell Cycle C | 2018 |
Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Topics: Angiogenesis Inhibitors; Benzamides; Cell Line, Tumor; Epigenesis, Genetic; Eye Proteins; Female; Ge | 2019 |
Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers; CD24 Antigen; Cell Line, Tumor; Disease Mode | 2015 |